Actinium

Actinium (symbol Ac, atomic number 89) is a radioactive, silvery-white metallic chemical element and the prototype of the actinide series, located in period 7 of the f-block of the periodic table between radium and thorium. Discovered in 1899 in the residues of uranium ore, it has no stable isotopes, emits intense radiation that ionizes the surrounding air into a faint pale-blue glow, and exists in nature only in minute traces within uranium and thorium ores. Its chemistry closely resembles that of the lanthanide element lanthanum, and its principal isotope, actinium-227, has found practical uses ranging from neutron sources to, in recent decades, emerging applications in targeted alpha-particle cancer therapy.

History and Etymology

Actinium was discovered in 1899 by the French chemist André-Louis Debierne, an assistant to Marie and Pierre Curie, while he was separating rare-earth fractions from pitchblende residue left over after the extraction of radium and polonium. He observed new radioactive activity in the fractions and announced the finding of a new element, which he named actinium, derived from the Greek word aktinos (ἀκτίνος), meaning "ray" or "beam," in recognition of its intense radioactivity.

Independently, the German chemist Friedrich Oskar Giesel isolated a similar radioactive substance around 1901–1902 from uranium ore and named it emanium. Subsequent investigations showed that the two substances were identical; however, because Debierne's priority in publication was generally accepted, the name actinium was retained, and Giesel's designation emanium was abandoned.

For several decades, actinium was studied almost exclusively as a source of radiation, and its chemical identity remained poorly resolved. In 1939, the French physicist Marguerite Perey discovered that a small fraction of actinium-227 atoms decay by alpha emission to a hitherto unknown element, which she identified and named francium, thereby establishing actinium-227 as the parent nuclide of francium in nature. In 1945, Glenn T. Seaborg proposed the actinide concept, grouping actinium and the following heavy elements into a series analogous to the lanthanides; the series was named the actinides in honor of actinium. Metallic actinium itself proved extremely difficult to obtain because of the element's scarcity and intense radioactivity, and it was not isolated in pure form until 1947, when actinium fluoride was reduced with lithium vapor in a vacuum furnace at approximately 1100–1200 °C.

Occurrence and Production

Actinium occurs in nature solely as the decay products of primordial uranium and thorium. The isotope actinium-227 belongs to the uranium-235 decay series (the actinium series, or 4n+3 series) and is found in uranium ores in extremely small amounts—on the order of 0.2 milligrams per tonne of natural uranium. Actinium-228, with a half-life of only about six hours, arises in the thorium-232 decay series, and trace quantities of actinium-225 occur in the uranium-235 chain. Because of these vanishingly small natural concentrations, direct extraction from ores is impractical.

Virtually all actinium used in research and medicine is produced artificially. The most important route involves neutron irradiation of radium-226 in a nuclear reactor, producing radium-227, which beta-decays to actinium-227 with a half-life of about 42 minutes; the resulting actinium is then separated chemically from the radium target. The medically significant isotope actinium-225 is obtained from generators based on thorium-229 (itself a decay product of uranium-233 stockpiles) or, increasingly, by proton irradiation of thorium-232 targets in particle accelerators. Chemical separation from target materials is accomplished through classical radiochemical techniques, including coprecipitation with lanthanum salts, ion-exchange chromatography, and solvent extraction, exploiting the trivalent character that actinium shares with the lanthanides.

Physical Properties

Actinium is a soft, silvery-white metal that darkens rapidly on exposure to air owing to the formation of a surface oxide layer. Its most striking physical characteristic is the pale blue luminescence it causes in the dark: the intense radiation emitted by actinium and its decay products ionizes the surrounding air, producing a visible glow. The metal has a density of about 10.07 g/cm³, a melting point of approximately 1050 °C, and an estimated boiling point near 3200 °C. At room temperature it crystallizes in a face-centered cubic structure. Its electron configuration is [Rn] 6d¹ 7s², which places it formally at the head of the actinide series. Because its trivalent ion possesses no unpaired f-electrons, actinium is essentially diamagnetic, in contrast to most of the heavier actinides.

Chemical Properties

Actinium behaves chemically as a strongly electropositive metal. In essentially all of its compounds it exhibits the +3 oxidation state, mirroring the behavior of the lanthanides—particularly lanthanum—and its Ac³⁺ ion is among the largest trivalent ions in the periodic table, with an ionic radius slightly exceeding that of La³⁺. This close chemical similarity between actinium and lanthanum has made lanthanum a standard nonradioactive carrier and surrogate in actinium chemistry.

When finely divided, the metal burns in air; it reacts readily with water to form actinium hydroxide and hydrogen gas, and combines directly with hydrogen to yield hydrides. Its principal inorganic compounds include the sesquioxide Ac₂O₃, the hydroxide Ac(OH)₃, the trihalides AcF₃, AcCl₃, and AcBr₃, and a range of oxysalts such as the nitrate, sulfate, phosphate, and oxalate. Actinium fluoride is notably insoluble, and the insolubility of actinium oxalate and fluoride has historically been exploited in its precipitation and purification. Actinium compounds are colorless to white, since the Ac³⁺ ion has no f-electrons to absorb visible light.

Isotopes and Radioactivity

All actinium isotopes are radioactive. More than thirty isotopes are known, spanning mass numbers from about 204 to 236, but three are of particular importance:

• Actinium-227 (half-life 21.77 years) is the only long-lived isotope and constitutes essentially all naturally occurring actinium. It decays 98.6% by beta emission to thorium-227 and 1.4% by alpha emission to francium-223. Its decay chain passes through radium-223, radon-219, and a series of short-lived nuclides before terminating in stable lead-207. One gram of actinium-227 has an activity of roughly 2.7 terabecquerels (about 74 curies).
• Actinium-225 (half-life 9.92 days) decays by alpha emission through francium-221 and astatine-217 to bismuth-213; its chain releases approximately four alpha particles per decay, delivering about 28 MeV of alpha energy—a property central to its use in alpha therapy.
• Actinium-228 (half-life 6.15 hours) is a strong beta emitter produced in the thorium-232 series.

The intense, multi-particle radiation from actinium and its daughters makes the element exceptionally radiotoxic if inhaled or ingested, as trivalent actinium behaves like the lanthanides and is deposited mainly in the skeleton and liver. All handling of macroscopic quantities requires sealed enclosures, remote manipulation, and heavy shielding against the penetrating gamma radiation emitted by decay daughters such as lead-211.

Applications

The practical uses of actinium derive almost entirely from the radioactivity of its isotopes. Historically, actinium-227 was employed as a source of alpha particles in early radiotherapy research, and when alloyed with or mixed with beryllium it serves as an efficient neutron source: alpha particles emitted by actinium and its daughters strike beryllium nuclei, releasing neutrons. Such actinium–beryllium sources have been used for neutron radiography, well logging, and research, and they possess the advantage of comparatively low gamma output relative to older radium–beryllium sources.

The most significant contemporary application is in nuclear medicine. Actinium-225 is one of the most promising radionuclides for targeted alpha therapy, in which the isotope is bound to a chelator and a targeting molecule that delivers alpha radiation specifically to cancer cells. Conjugates such as ²²⁵Ac-PSMA-617, directed at prostate-specific membrane antigen in metastatic prostate cancer, and ²²⁵Ac-DOTATATE, aimed at neuroendocrine tumors, have shown striking therapeutic responses in clinical trials. The short path length of alpha particles (a few cell diameters) allows destruction of tumor cells with minimal damage to surrounding healthy tissue, though limited global supply of actinium-225 remains a major constraint on wider clinical deployment.

Significance

Actinium holds an important place in the history of radiochemistry and nuclear science. Its discovery, alongside radium and polonium, marked the formative era of radioactivity research, and its decay provided the route to the discovery of francium, the last of the naturally occurring elements to be identified. The element gave its name to the actinide series, the row of fifteen heavy radioactive metals that includes thorium, uranium, and plutonium—the elements that define the nuclear age—and actinium chemistry served as an early template for understanding the lanthanide-like behavior that characterizes the early actinides. In the twenty-first century, actinium has acquired renewed importance as a cornerstone of targeted alpha therapy, positioning it at the intersection of fundamental radiochemistry and frontier oncology, while its scarcity and radiotoxicity continue to pose the technical challenges that have defined the element since its discovery.